Method and system for detecting ritonavir intermediate
By combining reversed-phase high-performance liquid chromatography (RP-HPLC) with an ultraviolet detector, the problem of detecting ritonavir intermediates has been solved, enabling controllable drug quality and safety, and ensuring rapid and accurate detection of ritonavir intermediates.
Patent Information
- Application Number
- CN202411074762.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-15
AI Technical Summary
The lack of effective detection methods for ritonavir intermediates in the current technology affects drug quality control and the safety of clinical use.
The intermediates of ritonavir were detected using reversed-phase high-performance liquid chromatography with a UV detector, a specific mobile phase, and a gradient elution program. The specific steps included sample solution preparation and chromatogram recording.
Rapid and accurate detection of ritonavir intermediates was achieved, ensuring the controllability and safety of drug quality, with separation and detection limits meeting requirements.
Smart Images

Figure CN118961932A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of ritonavir intermediate detection, and in particular to a ritonavir intermediate detection method and system. Background Art
[0002] (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride is an intermediate of ritonavir, which is an anti-human immunodeficiency virus (HIV) drug and an HIV protease inhibitor. It is indicated for the treatment of advanced or non-progressive AIDS patients alone or in combination with antiretroviral nucleoside drugs. In particular, its combination with Nirmatrelvir can significantly reduce the ability of the new coronavirus to reproduce in the body. In the research and development of new and generic drugs, impurities are the key quality attributes that affect the products. The control of impurities is also one of the difficulties in drug research and development. In addition to being related to the pharmacological activity of the main ingredients, the adverse reactions of drugs in clinical use are also closely related to the impurities present in the drugs.
[0003] (2S,3S,5S)-5-Amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride, English name is (2S,3S,5S)-5-Amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-di phenyl-3-hydroxyhexane, molecular formula is C23H28ClN3O3S, molecular weight is 462.01, CAS number is 144164-11-4, chemical structure is as follows:
[0004]
[0005] According to the concept of source control and process control, the preparation of (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride also needs to establish an effective detection method for strict control. After searching, no relevant patents or public literature reports on the detection method of ritonavir intermediates have been found. Summary of the invention
[0006] The present disclosure aims to solve at least one of the technical problems existing in the prior art, and proposes a ritonavir intermediate detection method and system.
[0007] In the first aspect, the present disclosure provides a method for detecting a ritonavir intermediate, wherein the molecular formula is C 23 H 28 ClN3O3S, the structural formula is
[0008]
[0009] The following steps are involved:
[0010] S1, take (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride, dissolve it in acetonitrile-water as a diluent, and quantitatively dilute it to prepare a mixed solution containing 1.0 mg of (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride per 1 ml of diluent to obtain a sample solution;
[0011] S2, take 5 μl of the sample solution and inject it into the liquid chromatograph, record the chromatogram, and complete the detection of the ritonavir intermediate.
[0012] Preferably, the detection of the ritonavir intermediate is completed by reversed-phase high performance liquid chromatography and a UV detector, and the detection conditions of the reversed-phase high performance liquid chromatography are as follows:
[0013] Octadecylsilane bonded silica gel was used as the chromatographic column filler, and the column temperature was 43-47°C;
[0014] Phase A is a mixed solution of ammonium acetate buffer, acetonitrile and trifluoroacetic acid, wherein the volume ratio of ammonium acetate buffer, acetonitrile and trifluoroacetic acid is 90:10:0.15;
[0015] Phase B is a mixed solution of methanol, acetonitrile and trifluoroacetic acid, wherein the volume ratio of methanol, acetonitrile and trifluoroacetic acid is 70:30:0.15; the flow rate is 1.1-1.3 ml / min; the elution program is gradient elution; the injector temperature is 4°C; and the detection wavelength is 210 nm.
[0016] Preferably, the molar concentration of the ammonium acetate buffer is 0.018 mol / L to 0.022 mol / L.
[0017] Preferably, the molar concentration of the ammonium acetate buffer is 0.02 mol / L.
[0018] Preferably, the gradient elution procedure is:
[0019] At 0-1min, the proportion of phase B is 5%;
[0020] In 1 to 10 min, the proportion of phase B changes from 5% to 70%;
[0021] At 10-15 min, the proportion of phase B is 70%;
[0022] At 15-15.1 min, the proportion of phase B changed from 70% to 5%;
[0023] At 15.1-20 min, the proportion of phase B is 5%.
[0024] Preferably, the injection volume of the injector is 5 μl.
[0025] Preferably, the volume ratio of acetonitrile to water is 20:80.
[0026] On the other hand, the present invention also provides a ritonavir intermediate detection system, which can be used to implement the ritonavir intermediate detection method described in any one of claims 1 to 7 above, and the system comprises:
[0027] a sample preparation module, for taking (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride, dissolving it in acetonitrile-water as a diluent, and quantitatively diluting it to prepare a mixed solution containing 1.0 mg of (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride per 1 ml of the diluent, to obtain a sample solution;
[0028] The detection module is used to take 5 μl of sample solution and inject it into the liquid chromatograph, record the chromatogram, and complete the detection of ritonavir intermediates. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 It is a chromatogram of a blank solution in an embodiment of the present invention;
[0030] Figure 2 It is a chromatogram of the separation solution in the embodiment of the present invention;
[0031] Figure 3 It is a chromatogram of the test solution in the implementation case of the present invention. DETAILED DESCRIPTION
[0032] In order to enable those skilled in the art to better understand the technical solution of the present disclosure, the present disclosure is further described in detail below in conjunction with the accompanying drawings and specific implementation methods.
[0033] In each of the accompanying drawings, the same elements are represented by similar reference numerals. For the sake of clarity, the various parts in the accompanying drawings are not all drawn to scale. In addition, some well-known parts may not be shown in the drawings.
[0034] Many specific details of the present disclosure are described below, such as component structures, materials, dimensions, processing techniques, and technologies, in order to more clearly understand the present disclosure. However, as those skilled in the art will appreciate, the present disclosure may be implemented without following these specific details.
[0035] like Figure 1 As shown, the embodiment of the present invention provides a method for detecting a ritonavir intermediate, the molecular formula of which is C 23 H 28 ClN3O3S, the structural formula is
[0036]
[0037] The following steps are involved:
[0038] S1, taking (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride, dissolving it in acetonitrile-water (20:80) as a diluent, and quantitatively diluting it to prepare a mixed solution containing 1.0 mg of (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride per 1 ml of the diluent to obtain a sample solution;
[0039] S2, take 5 μl of the sample solution and inject it into the liquid chromatograph, record the chromatogram, and complete the detection of the ritonavir intermediate.
[0040] The present invention adopts acetonitrile-water (20:80) as a diluent, thereby solving the solubility problem of the test sample and the stability problem of the sample solution; and the preparation method is simple and easy to operate, and can achieve baseline separation of the separation degree of each related substance, and can simply, quickly and accurately detect the content of each related substance.
[0041] Specifically, the reverse phase high performance liquid chromatography method is used to detect the ritonavir intermediate using a UV detector. The HPLC (high performance liquid chromatography) detection conditions are as follows:
[0042] Chromatographic column: Agilent Poroshell 120EC-C18 (100 mm × 4.6 mm, 2.7 μm) chromatographic column, with octadecylsilane bonded silica gel as the chromatographic column filler, column temperature 43-47 ° C;
[0043] The mobile phase includes phase A and phase B: phase A is a mixed solution of ammonium acetate buffer, acetonitrile and trifluoroacetic acid, wherein the volume ratio of ammonium acetate buffer, acetonitrile and trifluoroacetic acid is 90:10:0.15; phase B is a mixed solution of methanol, acetonitrile and trifluoroacetic acid, wherein the volume ratio of methanol, acetonitrile and trifluoroacetic acid is 70:30:0.15; the flow rate is 1.1-1.3 ml / min; the elution program is gradient elution; the injector temperature is 4°C; the detection wavelength is 210 nm. The molar concentration of the ammonium acetate buffer is 0.018 mol / L-0.022 mol / L.
[0044] Among them, in the mixed phase of phase A and phase B, the proportion of phase B in the mixed phase changes continuously as the gradient elution program proceeds, and the specific changes are as follows:
[0045] At 0-1min, the proportion of phase B is 5%;
[0046] In 1 to 10 min, the proportion of phase B changes from 5% to 70%;
[0047] At 10-15 min, the proportion of phase B is 70%;
[0048] At 15-15.1 min, the proportion of phase B changed from 70% to 5%;
[0049] At 15.1-20 min, the proportion of phase B is 5%.
[0050] In a specific implementation scenario, a ritonavir intermediate detection method disclosed in the present invention identifies 8 impurities as follows for its synthesis process:
[0051]
[0052] By screening the chromatographic conditions, eight impurities can be effectively separated, a related substance detection method is established, and the analysis time is controlled within 20 minutes. The separation degree between the main component and each related substance is not less than 1.5, and the separation degree between each related substance is not less than 1.2, thereby achieving the purpose of the above invention.
[0053] The specific HPLC detection chromatographic conditions are as follows:
[0054] Chromatographic conditions: octadecylsilane bonded silica gel was used as filler (Agilent poroshell 120EC-C18 (100×4.6mm, 2.7μm) was suitable or equivalent chromatographic column); ammonium acetate buffer (1.54g ammonium acetate was weighed, dissolved in 1000ml water, filtered, and ultrasonicated)-acetonitrile-trifluoroacetic acid (90:10:0.15) was used as mobile phase A; methanol-acetonitrile-trifluoroacetic acid (70:30:0.15) was used as mobile phase B; the flow rate was 1.2ml per minute; the injector temperature was 4℃; the column temperature was 45℃; the detection wavelength was 210nm; the injection volume was 5μl; gradient elution was performed as shown in the following table:
[0055] Time (min) <![CDATA[ A (%)]]> B(%) 0 95 5 1 95 5 10 30 70 15 30 70 15.1 95 5 20 95 5
[0056] Separation solution: Take appropriate amounts of (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride, impurity A, impurity B, impurity C, impurity D, impurity E, impurity F, and impurity G, accurately weigh them, add acetonitrile-water (20:80) to dissolve and quantitatively dilute to a mixed solution containing about 1 mg of (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride, about 1.5 μg of impurity A, about 1.5 μg of impurity B, about 1.5 μg of impurity C, about 1.5 μg of impurity D, about 1.5 μg of impurity E, about 5.0 μ of impurity F, about 10.0 μ of impurity G, and about 5.0 μ of impurity H per 1 ml.
[0057] Test solution: Take an appropriate amount of the product, weigh accurately, dissolve in acetonitrile-water (20:80) and quantitatively dilute to make a solution containing about 1.0 mg per 1 ml.
[0058] Blank solution chromatogram Figure 1 , the separation solution chromatogram is shown in Figure 2 , the chromatogram of the test solution is shown in Figure 3 .
[0059] The following table shows the detection limit data results in the implementation case of the present invention:
[0060]
[0061] The following table shows the quantitative limit data results of 6 consecutive injections in the implementation case of the present invention:
[0062]
[0063] The following table shows the linear data results in the implementation case of the present invention:
[0064]
[0065] The following table shows the durability data results in the implementation cases of the present invention:
[0066]
[0067] The embodiment of the present invention also provides a ritonavir intermediate detection system, which can be used to implement the above-mentioned ritonavir intermediate detection method, and the system includes:
[0068] a sample preparation module, for taking (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride, dissolving it in acetonitrile-water as a diluent, and quantitatively diluting it to prepare a mixed solution containing 1.0 mg of (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride per 1 ml of the diluent, to obtain a sample solution;
[0069] The detection module is used to take 5 μl of sample solution and inject it into the liquid chromatograph, record the chromatogram, and complete the detection of ritonavir intermediates.
[0070] It is to be understood that the above embodiments are merely exemplary embodiments used to illustrate the principles of the present disclosure, but the present disclosure is not limited thereto. For those of ordinary skill in the art, various modifications and improvements can be made without departing from the spirit and substance of the present disclosure, and these modifications and improvements are also considered to be within the scope of protection of the present disclosure.
Claims
1. A method for detecting a ritonavir intermediate, the molecular formula of which is C 23 H 28 ClN3O3S, the structural formula is It is characterized in that The following steps are involved: S1, take (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride, dissolve it in acetonitrile-water as a diluent, and quantitatively dilute it to prepare a mixed solution containing 1.0 mg of (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride per 1 ml of diluent to obtain a sample solution; S2, take 5 μl of the sample solution and inject it into the liquid chromatograph, record the chromatogram, and complete the detection of the ritonavir intermediate.
2. The method for detecting ritonavir intermediates according to claim 1, characterized in that: The detection of ritonavir intermediates was completed by reverse phase high performance liquid chromatography and a UV detector. The detection conditions of the reverse phase high performance liquid chromatography are as follows: Octadecylsilane bonded silica gel was used as the chromatographic column filler, and the column temperature was 43-47°C; Phase A is a mixed solution of ammonium acetate buffer, acetonitrile and trifluoroacetic acid, wherein the volume ratio of ammonium acetate buffer, acetonitrile and trifluoroacetic acid is 90:10:0.15; Phase B is a mixed solution of methanol, acetonitrile and trifluoroacetic acid, wherein the volume ratio of methanol, acetonitrile and trifluoroacetic acid is 70:30:0.15; the flow rate is 1.1-1.3 ml / min; the elution program is gradient elution; the injector temperature is 4°C; and the detection wavelength is 210 nm.
3. The method for detecting ritonavir intermediates according to claim 2, characterized in that: The molar concentration of the ammonium acetate buffer is 0.018 mol / L to 0.022 mol / L.
4. The method for detecting ritonavir intermediates according to claim 3, characterized in that: The molar concentration of the ammonium acetate buffer is 0.02 mol / L.
5. The method for detecting ritonavir intermediates according to claim 2, characterized in that: The gradient elution procedure is: At 0-1min, the proportion of phase B is 5%; In 1 to 10 min, the proportion of phase B changes from 5% to 70%; At 10-15 min, the proportion of phase B is 70%; At 15-15.1 min, the proportion of phase B changed from 70% to 5%; At 15.1-20 min, the proportion of phase B is 5%.
6. The method for detecting ritonavir intermediates according to claim 2, characterized in that: The injection volume of the injector is 5 μl.
7. The method for detecting ritonavir intermediates according to claim 1, characterized in that: The volume ratio of acetonitrile to water is 20:
80.
8. A ritonavir intermediate detection method, characterized in that: The system can be used to implement the ritonavir intermediate detection method described in any one of claims 1 to 7, and the system comprises: a sample preparation module, for taking (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride, dissolving it in acetonitrile-water as a diluent, and quantitatively diluting it to prepare a mixed solution containing 1.0 mg of (2S, 3S, 5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane hydrochloride per 1 ml of the diluent, to obtain a sample solution; The detection module is used to take 5 μl of sample solution and inject it into the liquid chromatograph, record the chromatogram, and complete the detection of ritonavir intermediates.
